YOLFTbeta
Blinklab Ltd

Blinklab Ltd

BB1 · AU · Healthcare / Health Information Services

0.59AUD-0.01 (-1.67%)

Price History

Full chart

Market Stats

Previous Close0.60
Open0.60
Day Range0.58 – 0.60
52-Week Range0.52 – 1.11
Volume60.40K
Market Cap116.37M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.05
Dividend Yield0.00%
Beta1.34
50-Day Avg0.7183
200-Day Avg0.7529

About

BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing. Its smartphone-based application serves as a device for conducting neurobehavioral evaluations and objective sensorimotor biomarkers, which provides scientific support for future regulatory approval and clinical adoption. The company's application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), and various forms of dementia. The company was incorporated in 2021 and is based in Perth, Australia.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEODr. Hendrikus Johannes Boele M.D., Ph.D.
  • Employees0
  • Headquarters216 St Georges Tce, Perth, WA, Australia, 6000, Australia
  • Websitehttps://www.blinklab.org

Leadership

  • Dr. Hendrikus Johannes Boele M.D., Ph.D.Co-Founder, CEO, MD & Director
  • Dr. Anton Uvarov BioChem, MBA, MedGen, Ph.D.Co-Founder, COO & Executive Director
  • Mr. Cornelis Peter Boele M.A.Co-Founder & CTO
  • Dr. Sebastiaan K.E Koekkoek Ph.D.Co-Founder & Chief Quality and Regulatory Officer
  • Myrthe Ottenhoff M.D., Ph.D.Chief Medical Officer
  • Mr. Christopher Bryan James Achurch B.Com., C.A.Company Secretary

Financials

Income Statement

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue0036.96K375.55K-
Growth (%)---+916.10%-
Operating Income-483.15K-675.06K-1.75M-5.70M-8.42M
Operating Margin---4731.44%-1517.04%-
EBITDA--619.25K-1.67M-5.57M-6.81M
EBITDA Margin---4510.63%-1483.27%-
Net Income-485.15K-676.38K-1.75M-5.71M-7.22M
Net Income Margin---4743.70%-1519.67%-
R&D--180.13K2.60M4.68M
R&D as % of Total Revenue--487.35%692.29%-
Interest Expense-1.32K4.53K9.88K21.38K
Interest Expense % of Total Revenue--12.26%2.63%-

Balance Sheet

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets911.49K370.13K6.87M9.67M20.56M
Total Liabilities194.39K329.41K386.18K700.73K1.06M
Total Equity717.10K40.72K6.48M8.97M19.50M
Cash616.91K50.06K1.02M1.71M7.88M

Cash Flow

Currency: AUD2022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-303.33K-473.34K-1.75M-4.17M-
Investing Cash Flow-264.86K-83.07K-3.14M2.86M-
Financing Cash Flow1.19M-14.20K7.87M6.99M16.77M
Capital Expenditure264.86K83.07K143.96K135.52K1.30M
Free Cash Flow--556.41K-1.90M-4.30M-7.54M
FCF to OCF-117.55%108.21%103.25%-

Earnings

Report DateFeb 26, 2025Aug 28, 2025
EPS Estimate0.000.00
EPS Actual-0.02-0.04
Surprise--
Timing--

Key Statistics & Ratios

Market Cap116.37M
Enterprise Value96.17M
Trailing P/E0.00
Forward P/E0.00
Price / Sales96.37
Price / Book5.83
EPS-0.05
Book Value0.128
Revenue (TTM)1.21M
Gross Profit (TTM)719.73K
EBITDA-6.99M
Profit Margin0.00%
Operating Margin-319.17%
Return on Equity-50.72%
Return on Assets-29.11%
Shares Outstanding176.33M
Shares Float97.37M
Beta1.34
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%